Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways

Title
Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways
Authors
Keywords
Inflammatory breast cancer, Syndecan-1, Proteoglycan, Cancer stem cell, IL-6/STAT3, Notch, EGFR
Journal
Molecular Cancer
Volume 16, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-03-07
DOI
10.1186/s12943-017-0621-z

Ask authors/readers for more resources

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started